Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

Lamivudine

  • Free
    Repurposing Nucleoside Analogs for Human Coronaviruses
    Antiviral Agents
    Repurposing Nucleoside Analogs for Human Coronaviruses

    Coronavirus disease 2019 (COVID-19) is a serious illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or CoV-2). Some reports claimed certain nucleoside analogs to be active against CoV-2 and thus needed confirmation. Here, we evaluated a panel of compounds and identified novel nucleoside analogs with antiviral activity against CoV-2 and HCoV-OC43 while ruling out others. Of significance, sofosbuvir demonstrated...

    Keivan Zandi, Franck Amblard, Katie Musall, Jessica Downs-Bowen, Ruby Kleinbard, Adrian Oo, Dongdong Cao, Bo Liang, Olivia O. Russell, Tamara McBrayer, Leda Bassit, Baek Kim, Raymond F. Schinazi
  • Antiviral Agents
    Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals
    Sergio Serrano-Villar, Giorgia Caruana, Alexander Zlotnik, José A. Pérez-Molina, Santiago Moreno
  • Antiviral Agents
    Synergistic Interactions between Hepatitis B Virus RNase H Antagonists and Other Inhibitors
    Elena Lomonosova, Adam Zlotnick, John E. Tavis
  • Pharmacology
    Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding
    Frantz Foissac, Jörn Blume, Jean-Marc Tréluyer, Thorkild Tylleskär, Chipepo Kankasa, Nicolas Meda, James K. Tumwine, Mandisa Singata-Madliki, Kim Harper, Silvia M. Illamola, Naïm Bouazza, Nicolas Nagot, Philippe Van de Perre, Stéphane Blanche, Déborah Hirt
    and for the ANRS 12174 Trial Group
  • Pharmacology
    Importance of Serum Concentration of Adefovir for Lamivudine-Adefovir Combination Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B
    Fukiko Mitsui, Masataka Tsuge, Takashi Kimura, Shosuke Kitamura, Hiromi Abe, Hiromi Saneto, Tomokazu Kawaoka, Daiki Miki, Tsuyoshi Hatakeyama, Nobuhiko Hiraga, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Shoichi Takahashi, C. Nelson Hayes, Harue Igarashi, Kentaro Morimoto, Masao Shimizu, Kazuaki Chayama
  • Antiviral Agents
    Is the Recommended Once-Daily Dose of Lamivudine Optimal in West African HIV-Infected Children?
    Naïm Bouazza, Déborah Hirt, Christophe Bardin, Serge Diagbouga, Boubacar Nacro, Hervé Hien, Emmanuelle Zoure, François Rouet, Adama Ouiminga, Stephane Blanche, Philippe Van De Perre, Jean-Marc Tréluyer, Philippe Msellati, Saik Urien
  • Antiviral Agents
    Randomized Controlled Study Investigating Viral Suppression and Serological Response following Pre-S1/Pre-S2/S Vaccine Therapy Combined with Lamivudine Treatment in HBeAg-Positive Patients with Chronic Hepatitis B
    Pham Thi Le Hoa, Nguyen Tien Huy, Le The Thu, Cao Ngoc Nga, Kazuhiko Nakao, Katsumi Eguchi, Nguyen Huu Chi, Bui Huu Hoang, Kenji Hirayama
  • Antiviral Agents
    Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy
    Constance Delaugerre, Philippe Flandre, Marie Laure Chaix, Jade Ghosn, François Raffi, Pierre Dellamonica, H. Jaeger, D. Shürmann, Isabelle Cohen-Codar, Philippe Ngo Van, Michael Norton, Anne-Marie Taburet, Jean-François Delfraissy, Christine Rouzioux
    and for the MONARK Study Group
  • Antiviral Agents
    Virologic Failure in First-Line Human Immunodeficiency Virus Therapy with a CCR5 Entry Inhibitor, Aplaviroc, plus a Fixed-Dose Combination of Lamivudine-Zidovudine: Nucleoside Reverse Transcriptase Inhibitor Resistance Regardless of Envelope Tropism
    James F. Demarest, Heather Amrine-Madsen, David M. Irlbeck, Kathryn M. Kitrinos
    and on behalf of the CCR102881 Clinical Study Team
  • Antiviral Agents
    High Levels of Zidovudine (AZT) and Its Intracellular Phosphate Metabolites in AZT- and AZT-Lamivudine-Treated Newborns of Human Immunodeficiency Virus-Infected Mothers
    Lucie Durand-Gasselin, Alain Pruvost, Axelle Dehée, Genevieve Vaudre, Marie-Dominique Tabone, Jacques Grassi, Guy Leverger, Antoine Garbarg-Chenon, Henri Bénech, Catherine Dollfus

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596